Nuvalent, Inc.'s New Drug Application (NDA) was accepted by the FDA for Priority Review.
4 reports, 1 independent
Updated May 27
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nuvalent, Inc.'s New Drug Application (NDA) was accepted by the FDA for Priority Review.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Nuvalent's NDA was accepted by the FDA for Priority Review.1 source
- Nuvalent aligned with FDA on NDA submission strategy.
- Nuvalent is seeking FDA approval for its cancer drug while market analysts and competitors monitor the progress.
Keep exploring
The entities involved
- FDA
-
Nuvalent, Inc. (United States)
company in Cambridge, United States
Nothing else this week.
Related events
- FDA approval supports NDA submission in Aurora.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
- Clene Inc. submitted an NDA to the FDA seeking accelerated approval while trading on the Nasdaq exchange.
- A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.
Coverage
Newest first; wire copies grouped- prnewswire.com
- Unknown outlet
- Unknown outlet
- Unknown outlet